Cargando…
Thalidomide Exerts Anti-Inflammatory Effects in Cutaneous Lupus by Inhibiting the IRF4/NF-ҡB and AMPK1/mTOR Pathways
Thalidomide is effective in patients with refractory cutaneous lupus erythematosus (CLE). However, the mechanism of action is not completely understood, and its use is limited by its potential, severe side-effects. Immune cell subset analysis in thalidomide’s CLE responder patients showed a reductio...
Autores principales: | Domingo, Sandra, Solé, Cristina, Moliné, Teresa, Ferrer, Berta, Cortés-Hernández, Josefina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698478/ https://www.ncbi.nlm.nih.gov/pubmed/34944673 http://dx.doi.org/10.3390/biomedicines9121857 |
Ejemplares similares
-
MicroRNAs in Several Cutaneous Autoimmune Diseases: Psoriasis, Cutaneous Lupus Erythematosus and Atopic Dermatitis
por: Domingo, Sandra, et al.
Publicado: (2020) -
IRF-8/miR-451a regulates M-MDSC differentiation via the AMPK/mTOR signal pathway during lupus development
por: Shi, Guoping, et al.
Publicado: (2021) -
An Exosomal Urinary miRNA Signature for Early Diagnosis of Renal Fibrosis in Lupus Nephritis
por: Solé, Cristina, et al.
Publicado: (2019) -
AMPK–mTOR Signaling and Cellular Adaptations in Hypoxia
por: Chun, Yoomi, et al.
Publicado: (2021) -
Humoral and cellular response in convalescent COVID-19 lupus patients
por: Solé, Cristina, et al.
Publicado: (2022)